Noneconomic Damages Caps Cut Malpractice Payments by 15%

This article originally appeared here.
Share this content:
Noneconomic Damages Caps Cut Malpractice Payments by 15%
Noneconomic Damages Caps Cut Malpractice Payments by 15%

(HealthDay News) -- Adoption of noneconomic damages caps reduces average malpractice payments by 15 percent, according to research published in the October issue of Health Affairs.

Seth A. Seabury, Ph.D., from the University of Southern California in Los Angeles, and colleagues estimated the impact of state noneconomic damages caps on average malpractice payment size using data from a national sample of malpractice claims for 1985 to 2010. They compared how the impact differed with cap restrictiveness ($250,000 versus $500,000).

The researchers found that, compared with having no cap, noneconomic damages caps reduced the average payments by 15 percent ($42,980). Compared with having no cap, average payments were reduced by 20 percent ($59,331) with a more restrictive $250,000 cap, while a less restrictive $500,000 cap had no significant impact. Physician specialty influenced the effect of the cap, with the largest impact on claims involving pediatricians and the smallest impact for claims involving surgical subspecialties and ophthalmologists.

"Future evaluations of malpractice reforms and the design of malpractice policy should consider both the types of physicians who are most likely to be affected by reforms and the differential impact that reforms may have depending on how restrictive they are," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »